Rising Stars Outlook 2016: New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)
Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there is a worldwide need for new therapies to treat the global epidemic of NASH and the cost to society will be huge if it is not addressed in the upcoming years! Besides, scarcity of treatment options, there is also an urgent unmet need to develop biomarkers that facilitate the diagnosis, identification of populations at risk, assessment of disease progression or regression, and/or response to treatment. The potential market is gigantic with analysts predicting north of $35bn by 2025!
Many small players are currently developing drugs on their own and with such a large unmet need, market potential and disease heterogeneity, we expect many Giants to join this race and thus, we can see more Licensing deals/M&A activity on the horizon! In light of recent developments in NASH, we have added few in-depth coverage of companies which either target early-stage NASH, late-stage NASH, or large pts pool-NAFLD in our Outlook this year.
Many small players are currently developing drugs on their own and with such a large unmet need, market potential and disease heterogeneity, we expect many Giants to join this race and thus, we can see more Licensing deals/M&A activity on the horizon! In light of recent developments in NASH, we have added few in-depth coverage of companies which either target early-stage NASH, late-stage NASH, or large pts pool-NAFLD in our Outlook this year.
LIST OF COMPANIES
1. Conatus Pharmaceuticals (CNAT)
2. Galectin Therapeutics (GALT)
3. Galmed Pharmaceuticals (GLMD)
4. Genfit SA (GNFT)
5. Intercept Pharmaceuticals (ICPT)
6. Tobira Therapeutics (TBRA)
1. Conatus Pharmaceuticals (CNAT)
2. Galectin Therapeutics (GALT)
3. Galmed Pharmaceuticals (GLMD)
4. Genfit SA (GNFT)
5. Intercept Pharmaceuticals (ICPT)
6. Tobira Therapeutics (TBRA)
More Publications
Global Rising Stars Outlook 2015: Innovative Therapies for Treating Diseases are Being Sought after with Fresh Vigor as New Targets
US$ 2,000.00
January 2015
72 pages
India Rising Stars Outlook 2015: Traditionally Innovation and Drug Discovery Had Taken a Back Seat in the Indian Pharma Industry with a Few Blips Here and There
US$ 1,000.00
January 2015
22 pages
Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars
US$ 2,500.00
January 2014
113 pages
